Ranbaxy Q4 net loss declines sharply to Rs 158.48 crore

Pharma major Ranbaxy Laboratories today reported a drastic drop in net loss at Rs 158.48 crore during the fourth quarter ended December 31, 2013.

The company had posted a net loss of Rs 492.44 crore in the corresponding quarter of the last financial year (2012-13), Ranbaxy said in a regulatory filing to the stock exchanges.

It had recorded a net loss of Rs 454.16 crore in Q3 of this fiscal.

Total income from operations of the company rose to Rs 2,893.99 crore from Rs 2,711.21 crore during the same period last year.

Earlier this month, Ranbaxy Laboratories signed an agreement with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab, prescribed to treat rheumatoid arthritis.

The product will be introduced in India and other emerging markets soon, the company had said.

Shares of the company were trading at Rs 328.70, up 2.16 per cent on the BSE.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • FDI in insurance must be allowed with a rider to increase penetration

    The Union cabinet has cleared the proposal to raise foreign direct investment (FDI) in the insurance sector through the FIPB route from the current 26

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Varun Dutt

Which is safer? Flying or driving?

The recent tragedies involving the Taiwan’s TransAsia Airways flight, and ...

Parvez Imam

Revisiting history can do us all good

We often think that we understand history. We read it ...

Bubbles Sabharwal

Your happiness doesn’t depend on your needs

They are two different words (and even worlds) altogether: having ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture